Results, announced Wednesday and presented at the 48th San Antonio Breast Cancer Symposium (SABCS), showed the Tukysa-based combo cut the risk of ...
News
- Pfizer Builds Case for Tukysa as 'New Standard Regimen' in First-Line Metastatic Breast Cancer
- NiKang Therapeutics Presents Discovery of NKT5097, a First-in-Class, Highly ... - Rutland Herald
... San Antonio Breast Cancer Symposium (SABCS 2025) being held December 9 ... NiKang Therapeutics is a clinical-stage biotech company focused on ...
- Wobble Genomics To Present New Data At SABCS Confirming Platform's Ability To ... - Morningstar
EDINBURGH, Scotland, Dec. 11, 2025 /PRNewswire/ -- Wobble Genomics, a biotechnology ... San Antonio, Texas. The data demonstrates the ability to ...
- Roche's Oral SERD Cuts Death Risk by 30% in Early-Stage Breast Cancer - BioSpace
Roche presented these findings at the 2025 San Antonio Breast Cancer Symposium (SABCS). ... biotech and science. He can be reached at tristan ...
- Celcuity Presents Updated Results from the PIK3CA Wild-Type Cohort of the Phase ... - StreetInsider
The additional study results were presented in an oral presentation session at the 2025 San Antonio Breast Cancer Symposium (“SABCS”) today, Thursday, ...